Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab long-term open-label extension in systemic sclerosis and other connective tissue disease-associated interstitial lung disease
CTR20251463Phase 3Active
- Sponsor
- GSK
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of belimumab in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD), connective tissue disease-associated interstitial lung disease (CTD-ILD), sponsored by GSK. Started Apr 2025; status: active.
02
Drugs
belimumab
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)connective tissue disease-associated interstitial lung disease (CTD-ILD)
Beyond the preview
Go deeper on CTR20251463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251463.